Migdal Insurance & Financial Holdings Ltd. Cardiff Oncology, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.97 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$6.65 - $10.04 $219,875 - $331,962	-33,064 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$9.1 - $19.57 $186,722 - $401,556	20,519 Added 163.56%	33,064 $306,000
Q4 2020 Feb 08, 2021	BUY	$12.02 - $24.71 $150,790 - $309,986	12,545 New	12,545 $226,000

Others Institutions Holding CRDF

# of Institutions

125

Shares Held

25.3M

Call Options Held

866K

Put Options Held

203K

Commodore Capital LP New York, NY

5.38M
Shares

$24.6 Million
2.34% of portfolio
Black Rock Inc. New York, NY

2.63M
Shares

$12 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.28M
Shares

$10.4 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

1.54M
Shares

$7.03 Million
0.18% of portfolio
Acorn Capital Advisors, LLC New York, NY

1.44M
Shares

$6.59 Million
3.38% of portfolio

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $198M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account